Eiso Hiyama

Professor

Hiroshima University

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Cancer Biology Cancer Biology professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Eiso Hiyama is a faculty member at Hiroshima University in Japan. His research focuses on cancer stemness, oncogenes in hepatoblastoma, and the molecular mechanisms underlying various malignancies. Recent publications include studies on the prognostic significance of EMX2 in esophageal squamous cell carcinoma and the role of ADAM32 in hepatoblastoma. He is also involved in comprehensive genomic profiling in prostate cancer and investigating circulating tumor cells in neuroblastoma.

Articles (18)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (6)

Genta Nagae

Project Associate Professor

University of Tokyo

JAPAN

View details

Keiji Tanimoto

Hiroshima University

JAPAN

View details

marc ansari

Head of the Cansearch Research platform for pediatric oncology and hematology, Faculty of Medicine

Université de Genève

SWITZERLAND

View details

Kirsten Kübler

University Hospital Bonn

GERMANY

View details

Tomoro Hishiki

Chiba University

JAPAN

View details

Fumiyuki Yamasaki

Associate Professor

Hiroshima University Hospital

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Eiso Hiyama

Research Interests

Explore related searches

Contact this professor

About

Articles (18)

Targeting HSP90 with Ganetespib to Induce CDK1 Degradation and Promote Cell Death in Hepatoblastoma

Unique Function in Cancer Stemness and Prognostic Significance of <i>EMX2</i> in Esophageal Squamous Cell Carcinoma

ADAM32 Oncogene in Hepatoblastoma Is Regulated by IGF2BP2

The RELIVE consortium for relapsed or refractory pediatric hepatoblastoma and hepatocellular carcinoma: a scoping review of the problem and a proposed solution.

Second Malignant Neoplasms Following Treatment for Hepatoblastoma: An International Report and Review of the Literature.

Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort study.

Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival.

Achaete-scute family bHLH transcription factor 2 activation promotes hepatoblastoma progression.

Optic tract edema in craniopharyngioma as a predictor of BRAFV600E mutation presence

Outcomes of Patients Treated for Hepatoblastoma with Low Alpha-Fetoprotein and/or Small Cell Undifferentiated Histology: A Report from the Children’s Hepatic Tumors International Collaboration (CHIC)

Increased plasma miR-370-3p expression in poor-outcome patients with pancreatic ductal adenocarcinoma.

Circulating Tumor Cells and Tumor Progression, Metastasis, and Poor Prognosis in Patients With Neuroblastoma.

Consensus classification of pediatric hepatocellular tumors: A report from the Children's Hepatic tumors International Collaboration (CHIC).

Transthoracic puncture for asymptomatic congenital pulmonary airway malformation during anesthesia.

COOBoostR: An Extreme Gradient Boosting-Based Tool for Robust Tissue or Cell-of-Origin Prediction of Tumors

In Vitro Transfection of Up-Regulated Genes Identified in Favorable-Outcome Neuroblastoma into Cell Lines

Oncogenic Role of ADAM32 in Hepatoblastoma: A Potential Molecular Target for Therapy

Feasibility of Real-Time Central Surgical Review for Patients with Advanced-Stage Hepatoblastoma in the JPLT3 Trial

Collaborators (6)

Genta Nagae

Keiji Tanimoto

marc ansari

Kirsten Kübler

Tomoro Hishiki

Fumiyuki Yamasaki

Make your next move.